Molecular Pharmacodynamics of New Oral Drugs Used in the Treatment of Multiple Sclerosis

Drug Design, Development and Therapy - New Zealand
doi 10.2147/dddt.s52428
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

The Changing Multiple Sclerosis Treatment Landscape: Impact of New Drugs and Treatment Recommendations

European Journal of Clinical Pharmacology
MedicinePharmacology
2018English

Drugs Used in the Treatment of Oral Mucosal Diseases

Yeditepe Dental Journal
2019English

Pnd65 - Cost-Effectiveness Analysis of Drugs Used for the Treatment of Highly Active Relapsing Multiple Sclerosis in Portugal

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Two New Drugs Hold Promise for the Treatment of Symptoms Associated With Multiple Sclerosis

Journal of the American Osteopathic Association, The
MedicineAlternative MedicineComplementary
1994English

Managing the Oral Side-Effects of Medications Used to Treat Multiple Sclerosis

Australian Dental Journal
Dentistry
2017English

A New Biotherapeutic Approach for the Treatment of Multiple Sclerosis

Translational Medicine
2013English

Chemotherapeutics in the Treatment of Multiple Sclerosis

Therapeutic Advances in Neurological Disorders
NeurologyPharmacology
2010English

Treatment of Multiple Sclerosis

Clinical Medicine and the Nervous System
1992English

Siponimod: A New Approved Oral Drug to Treat Multiple Sclerosis

NeuroPharmac Journal
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy